She assumed her current position as chief of nephrology at Nanfang Hos- pital, Southern Medical University, Guangzhou, China in 1999. Dr. Hou has been serving as Chair of the National Clinical Research Center for Kidney Disease since 2013. She is currently a councilor of the International Society of Nephrology and an Executive Committee member of KDIGO. Dr. Hou is a clinician scientist with an interest in kidney disease, speci cally the intervention of CKD and mechanisms underlying CKD progression. She had served as a steering committee member of international clinical trials, including ALBUM, SONAR, DAPA-CKD, and principal investigator of several national trials such as ESBARI, ROAD, and CSPPT- CKD. Dr. Hou has published hundreds of papers in peer- reviewed journals such as the New England Journal of Medi- cine, the Journal of the American Medical Association, Nature Medicine, the Journal of the American Society of Nephrology, and Kidney International. Consultancy: AstraZeneca Joachim H. Ix, MD, MAS, received his medical degree from the Uni- versity of Chicago, Pritzker School of Medicine, IL, USA. He trained in internal medicine and nephrology and subsequently joined the faculty at University of California San Francisco, CA, USA. He was recruited to University of California San Diego, CA, USA, in 2007 and has served as chief of the Division of Nephrology-Hypertension at University of Cali- fornia San Diego since 2013. Dr. Ix s research interests broadly focus on the overlap between kidney disease and vascular disease. His work has primarily utilized epidemiologic methods and clinical trials to understand disease patterns that overlap between kidney and vascular disease, and to test novel therapies to improve vascular disease in the kidney patient. 